Elorac, Inc. announced that it has acquired Gideon Pharmaceuticals, Inc. in an all-stock transaction.

Gideon Pharmaceuticals’ leading development-stage pharmaceutical products employ its patented Heprotect™ technology, which significantly reduces the hepatotoxicity of hepatocellular toxic agents without interfering with their bioactivity. Among the drugs being developed by Gideon are Heprotect versions of acetaminophen, methotrexate, acitretin and itraconazole, all compounds with established efficacy and side-effect profiles that include liver toxicity.

“We are pleased to have acquired Gideon’s recently patented technology for reducing the hepatotoxicity of certain pharmaceutical agents. Heprotect adds a platform technology with multiple applications to Elorac’s robust development pipeline,” said Jeffrey Bernstein, Ph.D., President and CEO of Elorac.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!